In an article published in the March 2011 issue of The Journal of Sexual Medicine, researchers from the Boston University School of Medicine seem to have confirmed what recent lawsuits have already alleged, namely that there is a link between the use of dutasteride (Avodart) and finasteride (Proscar and Propecia) and temporary and sometimes permanent sexual dysfunction including erectile dysfunction and loss of labido. Notably, more than double the percentage of men reported erectile dysfunction while on one of the drugs (8%) compared to placebo (4%). Further, a loss of sex drive was reported more than twice as frequently among those taking one of the drugs (4%) compared to placebo (1.8%). Other reported side effects of Avodart, Proscar and Propecia included depression, reduced semen production and growth of male breast tissue.
The most devastating information presented, however, relates to symptoms of the side-effects persisting even after the medication was discontinued. In fact, in a second study reported within the same volume of The Journal of Sexual Medicine, Dr. Michael S. Irwig interviewed 71 otherwise healthy men who reported sexual side effects after taking finasteride and determined the mean duration of the negative sexual impact to be 40 months after stopping the drug. Despite the absence of any such information on the drugs’ labeling in the United States, these prolonged side-effects do appear on the updated labeling for these drugs in European nations such as Great Britain, Sweden and Italy.
Merck’s Proscar (finasteride) was originally approved by the FDA in 1992 for the treatment of urinary problems because of the drug’s ability to decrease the size of an enlarged prostate by reducing the enzymes that turn testosterone into DHT, which represents the primary cause of prostate growth. However, enlarged prostate patients noticed that the drug also fostered hair growth in areas of the scalp where their hair had been thinning. Thus, Proscar, after being rebranded as Propecia, received approval from the FDA in 1997 for the treatment of male pattern baldness. Avodart, which was approved in 2002 for treatment of an enlarged prostate, is reportedly even more effective at supporting hair growth but has surprisingly not been submitted by GlaxoSmithKline to the FDA for approval of that additional indication. Perhaps knowledge of the potential long-term or permanent sexual side-effects, combined with the doubled risk of heart failure in men taking Avodart, as reported in The New England Journal of Medicine last March, is enough for GlaxoSmithKline to try to avoid increased exposure.
If you’re taking one of these drugs, speak to your doctor about whether these risks outweigh the benefits that you’re receiving from the use of these drugs. If you or a loved one have suffered from long-term or permanent sexual side-effects related to your use of one of these drugs, its important to find legal representation with a history of standing up to pharmaceutical companies. Contact Pogust Braslow & Millrood for a free consultation.